Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pulzium: A matter of risk


Pulzium: A matter of risk

FDA's Cardiovascular and Renal drugs advisory committee unanimously voted to recommend against approval of Pulzium tedisamil from Solvay S.A. to convert patients from atrial fibrillation to sinus rhythm based in part on what is known about the product, and even more on what isn't known.

The committee was worried by arrhythmias that occurred in patients who received Pulzium, and felt that results from Solvay's trials can't be generalized to the patients who would be exposed to the compound in the U.S.

In addition, the committee expressed concerns that the complex dosing and administration

Read the full 968 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers